– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –
See the article here:
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
COPENHAGEN, Denmark, March 10, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15.
Read more:
Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.
See original here:
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s liquidator (the “Liquidator”) today announced that Novelion has concluded the implementation of its plan of liquidation and distribution (the “Plan”) by winding down and dissolving the Company (the “Dissolution”).
Go here to read the rest:
Novelion Announces Completion of Plan of Liquidation and Distribution and its Voluntary Dissolution
Advisory Committee Meeting scheduled for May 19, 2023
BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its American Depositary Share ("ADS") to ordinary share ratio has been made effective. The ratio has changed from one ADS to one ordinary share to the new ratio of one ADS to ten ordinary shares.
See the original post here:
Orchard Therapeutics Completes ADS Ratio Change
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF FEBRUARY 2023 TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF FEBRUARY 2023
PORTLAND, Ore., March 10, 2023 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces that Mr. John Varghese has resigned from the Company’s Board of Directors (the “Board”) for personal reasons, effective immediately. Mr. Varghese was appointed to the Board on June 29, 2018 and served as Executive Chairman since September 2, 2019.
Follow this link:
Chalice Brands Ltd. Announces Resignation of Board Member
MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2022.
See the original post:
Medigene Amends 2022 Financial Guidance
Monthly information relative to the total number of voting rights and shares composing the share capital
See the rest here:
Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital